While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.
[in-text-ad]
Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

Skeptics of low-priced shares should remember that at one point Amazon, Apple and Netflix traded in the single digits. Nvidia, which has exploded higher on AI semiconductor chips, traded under $10 for years. One stock we featured over the years, Zynga, was purchased by Take-Two Interactive. Cogent Biosciences, which we featured last March, has tripled since then.

We screened our 24/7 Wall St. research database looking for smaller cap companies that could offer patient investors some huge returns for 2023 and beyond. These five stocks are rated Buy and have a ton of Wall Street coverage. Cathie Wood’s Ark Investments has been adding two of them, which in and of itself is a huge endorsement.

However, it is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

Adaptive Biotechnologies

Cathie Wood has bought almost 10 million shares of this stock for her Ark Genomic Revolution fund. Adaptive Biotechnologies Corp. (NASDAQ: ADPT) is a commercial-stage company that develops an immune medicine platform for the diagnosis and treatment of various diseases.

The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers.

In addition, Adaptive Biotechnologies offers a pipeline of clinical products and services that are used for the diagnosing, monitoring and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics and drug discovery applications. The company has strategic collaborations with Genentech for the development, manufacture and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers and with Microsoft to develop diagnostic tests for the early detection of various diseases from a single blood test.

Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.

This energy stock offers a solid dividend and good exposure to the sector, and it may be poised to be a big winner from provisions in the debt ceiling bill. Equitrans Midstream Corp. (NYSE: ETRN) owns, operates, acquires and develops natural gas gathering, transmission and storage, and water services assets in the Appalachian Basin. It operates through three segments:
[in-text-ad]

• Gathering System: This segment includes 1,130 miles of high-pressure gathering lines with compression of approximately 485,000 horsepower and multiple interconnect points, as well as approximately 910 miles of Federal Energy Regulatory Commission (FERC) low-pressure gathering lines.
• Transmission and Storage System: This segment comprises 950 miles of FERC-regulated interstate pipeline that connects to seven interstate pipelines and local distribution companies.
• Water Service System: This segment includes two independent systems, comprising approximately 200 miles of pipeline that deliver fresh water from the Monongahela River, the Ohio River, local reservoirs and various regional waterways.

Shareholders receive a 9.85% dividend. The Wolfe Research price target is $11, and Equitrans Midstream stock has a $7.56 consensus target. The shares closed on Friday at $9.08.

Genius Sports

This sports-betting-related stock has been hammered and holds massive upside potential, and it could even be a takeover target. Genius Sports Ltd. (NYSE: GENI) develops and sells technology-led products and services to the sports, sports betting and sports media industries.

The company offers technology infrastructure for the collection, integration and distribution of live data of sports leagues; streaming solutions, comprising of technology, automatic production and distribution for sports to commercialize video footage of their games; and end-to-end integrity services to sports leagues, such as full-time active monitoring technology, which uses mathematical algorithms to identify and flag suspicious betting activity in global betting markets, as well as full suite of online and offline educational and consultancy services.

Genius Sports also provides live sports data collection; pre-game and in-game odds feeds; risk management services, including customer profiling, monitoring of incoming bets, automated acceptance and rejection of bets, and limit setting; live streaming services; creation, delivery and measurement services for personalized online marketing campaigns; and fan engagement widgets for digital publishers that offer live game statistics and betting-related content.

Credit Suisse has set its price objective at $8, above the $7 consensus target. Genius Sports stock closed at $5.72 on Friday.

908 Devices

This is another Cathie Wood portfolio stock that also has the potential to be a huge winner. 908 Devices Inc. (NASDAQ: MASS) provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets. It operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
908 Devices products include:

• MX908, a handheld, battery-powered and Mass Spec device that is designed for rapid analysis of gas, liquid and solid materials of unknown identity
• Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses
• Maven and Trace C2, an online device for bioprocess monitoring and control
• ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.

[in-text-ad]
908 Devices has a $20 target price at SVB Leerink, while the consensus target is $17. On Friday, shares last changed hands at $9.09 apiece.

Plug Power

This company is poised to be a huge winner in the fuel cell battle for electric vehicles (EVs). Plug Power Inc. (NASDAQ: PLUG) delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road EVs, the stationary power market and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation and dispensing infrastructure.

The company offers the following:

• GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles
• GenFuel, a liquid hydrogen fueling delivery, generation, storage and dispensing system
• GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation and utility sectors
• GenKey, an integrated turn-key solution for transitioning to fuel cell power
• ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; liquefaction systems; and electrolyzers that are hydrogen generators optimized for clean hydrogen production
• GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive and GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products and ProGen fuel cell engines

The company sells its products through a direct product sales force, original equipment manufacturers and dealer networks.

The $24 UBS target price is well above the $18.89 consensus target and Friday’s $8.77 per share close for Plug Power stock.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.